Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + Anti-estrogen in HR+ HER2- Advanced Breast Cancer
NCT02291913Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Dec 2014
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in breast cancer, sponsored by SCRI Development Innovations. Primary endpoint: Progression Free Survival at 3 years. Started Dec 2014; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02291913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291913.